Pamidronate infusions as single-agent therapy for bone metastases: A phase II trial in patients with breast cancer
- 30 November 1995
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 31 (12) , 1976-1980
- https://doi.org/10.1016/0959-8049(95)00469-6
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosagesThe American Journal of Medicine, 1993
- Pharmacokinetics of Pamidronate in Patients With Bone MetastasesJNCI Journal of the National Cancer Institute, 1992
- Metastatic bone disease: Clinical and therapeutic aspectsBone, 1992
- Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD)British Journal of Cancer, 1988
- Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma.BMJ, 1988
- 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancerBritish Journal of Cancer, 1987
- The clinical course of bone metastases from breast cancerBritish Journal of Cancer, 1987
- Bone metastases and breast cancerCancer Treatment Reviews, 1985
- The Treatment of Cancer PainNew England Journal of Medicine, 1985
- DIAGNOSTIC PROCEDURES IN DISORDERS OF CALCIUM METABOLISMClinical Endocrinology, 1978